🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Ayahuasca modulation of traumatic-like fear memories requires infralimbic cortex BDNF-dependent mechanisms in rats.

PMID: 41411685 · DOI: 10.1016/j.euroneuro.2025.11.009 · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2026 · Isabel Werle, Francisco S Guimarães, Rafael G Dos Santos, Jaime E C Hallak, Leandro J Bertoglio
📄 Abstract

Rodent studies have shown that psychedelic drugs can enhance fear extinction. However, investigations to date have relied on normative aversive conditioning procedures, which limit their relevance to trauma-related memories, as these tend to be overgeneralized and resistant to extinction. Fear extinction depends on activity and plasticity within the infralimbic (IL) region of the medial prefrontal cortex and is regulated by brain-derived neurotrophic factor (BDNF). Ayahuasca (AYA), a brew containing the serotonergic psychedelic N,N-dimethyltryptamine (DMT), facilitates fear extinction in rodents and increases BDNF levels/signaling. Here, we investigated whether AYA attenuates extinction deficits and generalized fear induced by preconditioning restraint stress or high-intensity contextual fear conditioning, and whether these effects depend on BDNF-TrkB receptor signaling in the IL cortex. Adult male and female rats underwent the protocols above and received oral AYA one hour before each of the two extinction sessions conducted on consecutive days. Repeated administration of AYA containing 0.3 mg/kg of DMT enhanced extinction learning and its retention, effects that were abolished by bilateral intra-IL cortex infusion of an anti-BDNF antibody or the TrkB receptor antagonist ANA-12. AYA treatment also reduced fear generalization, an action that was BDNF-dependent in the IL cortex of females but not males. Overall, these findings indicate that AYA can modulate maladaptive fear memories through cortical mechanisms involving BDNF signaling, highlighting the potential of psychedelics as enhancers for extinguishing difficult-to-treat memories like those underlying post-traumatic stress disorder.

Confidence: 0.2 · 10 полей извлечено
Идентификация (6 полей)
Target
Brain-derived neurotrophic factor
1.00
Alt. target
BDNF
1.00
Protein family
Neurotrophin family
0.90
Functional class
Growth factor
0.90
Subcellular loc.
0.00
Isoforms (metab/obesity)
0.00
Механизм действия (21 полей)
Mechanism
0.00
Mutations (obesity/lean)
0.00
Activity (obesity)
0.00
Activity temporal
0.00
Energy balance
0.00
Appetite
0.00
Fat metabolism
0.00
Lipolysis
0.00
Thermogenesis
0.00
Muscle metabolism
0.00
Inflammation
0.00
Glucose metabolism
0.00
AA metabolism
0.00
Hormonal pathways
0.00
Cell death
0.00
Adipocyte fibrosis
0.00
Upstream (biochem)
0.00
Upstream (physiol)
0.00
Downstream (biochem)
0.00
Downstream (physiol)
0.00
PTMs
0.00
Экспрессия (8 полей)
Tissue expression
0.00
In vitro
0.00
In vivo
Ayahuasca (containing 0.3 mg/kg DMT) administered orally to adult male and female rats one hour before each of two extinction sessions enhanced extinction learning and retention, and reduced fear generalization; effects were blocked by intra-IL cortex infusion of anti-BDNF antibody or TrkB antagonist ANA-12.
0.95
In silico
0.00
Genetic association
0.00
Ex vivo
0.00
Animal model
Adult male and female rats
0.95
Diet/model
Preconditioning restraint stress or high-intensity contextual fear conditioning to induce extinction deficits and generalized fear
0.90
Клиника (11 полей)
Drug
Ayahuasca
1.00
Indication
Post-traumatic stress disorder (PTSD)
0.90
Patient subgroups
0.00
Safety concerns
0.00
Off-target
0.00
Trial stage
0.00
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
0.00
Approved
False
0.80